文献速递前列腺癌

基于PSMA-PET/CT的前列腺癌术后复发淋巴结图谱及挽救放疗临床意义

PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy.
PubMed 文献 · Eur Urol Oncol · 2020-05-22

该研究回顾性分析233例根治性前列腺切除及淋巴结清扫术后生化复发患者的799枚淋巴结转移灶,利用68Ga-PSMA-PET/CT构建三维彩色编码淋巴结图谱,评估RTOG临床靶区覆盖情况。结果显示标准RTOG CTV仅完全覆盖31.0%的转移淋巴结,PSA每升高1 ng/mL,CTV外转移风险增加1.43倍,提示高危患者挽救性盆腔放疗适用标准RTOG CTV可能不当。

要点

  • 标准RTOG CTV仅覆盖31.0%的淋巴结转移灶,多数未覆盖灶位于腹主动脉旁、直肠旁、膀胱旁、髋臼前、骶前及腹股沟区。
  • PET/CT时PSA水平是盆腔外淋巴结转移的最强预测因素,每升高1 ng/mL,CTV外转移风险增加1.43倍。
  • 高危前列腺癌术后生化复发患者行挽救性盆腔放疗时,应用标准RTOG CTV可能不合适。

核心结论

  • 标准RTOG CTV对高危前列腺癌术后复发患者淋巴结转移灶覆盖不足,仅31.0%完全覆盖,应用该CTV进行挽救性盆腔放疗可能不合适。

研究设计与样本

  • 回顾性筛选1653例68Ga-PSMA-PET/CT数据集,最终纳入233例根治性前列腺切除及淋巴结清扫术后生化复发患者,共799枚淋巴结转移灶。

主要发现

  • 标准RTOG CTV完全覆盖31.0%的淋巴结转移灶。
  • 未覆盖淋巴结主要位于腹主动脉旁、直肠旁、膀胱旁、髋臼前、骶前及腹股沟区。
  • PET/CT时PSA水平对盆腔外淋巴结转移预测价值最高,PSA每升高1 ng/mL,CTV外转移风险增加1.43倍。

关键数值与推荐

  • 标准RTOG CTV完全覆盖率为31.0%(全部淋巴结转移灶)。
  • PSA每升高1 ng/mL,CTV外转移风险增加1.43倍(优势比)。

临床怎么用

  • 高危前列腺癌术后生化复发患者行挽救性放疗时,应考虑标准RTOG CTV覆盖不足,结合PSMA-PET/CT结果个体化确定靶区。

局限性

  • 研究为回顾性设计,人群以高危患者为主,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients experience recurrence of prostate cancer after radical prostatectomy. OBJECTIVE: The aim of this study was to visually analyze typical patterns of lymph node (LN) involvement for prostate cancer (PC) patients with biochemical recurrence after radical prostatectomy and lymphadenectomy by creating a color-coded heat map using gallium-68 prostate-specific membrane antigen positron emission tomography (68Ga-PSMA-PET) imaging. Further, we evaluated which LNs were covered by the Radiation Therapy Oncology Group (RTOG) clinical target volume (CTV) contouring guidelines. DESIGN, SETTING, AND PARTICIPANTS: A total of 1653 68Ga-PSMA-PET/computed tomography (CT) datasets were screened retrospectively. After meeting the eligibility criteria, 233 patients with 799 LN metastases were included in our study. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We created a comprehensive three-dimensional color-coded LN atlas. Further, the coverage of LN metastases by RTOG CTV was assessed and stratification for risk factors was performed. RESULTS AND LIMITATIONS: In the overall, mainly high risk, collective, complete coverage by the standard RTOG CTV was accomplished in 31.0% of all LN metastases. The vast majority of uncovered LNs are situated in the para-aortal, pararectal, paravesical, preacetabular, presacral, and inguinal regions. Concerning examined stratification factors, prostate-specific antigen (PSA) levels at the time of PET/CT imaging had the highest predictive value for extrapelvic metastatic LN spread. Every increase of 1 ng/mL in PSA raises the risk of metastases outside the CTV by a factor of 1.43. CONCLUSIONS: We developed the first LN atlas for patients with recurrent PC using a heat map technique, in order to illustrate hot spots of LN recurrence. The vast majority of detected LNs are not covered by a standard CTV as recommended by the RTOG. Application of the standard RTOG CTV for pelvic irradiation in the salvage setting for high-risk PC patients seems to be inappropriate. PATIENT SUMMARY: We visualized typical lymph node recurrence sites for patients after prostate cancer surgery.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Schiller K, Stöhrer L, Düsberg M, et al. PSMA-PET/CT-based Lymph Node Atlas for Prostate Cancer Patients Recurring After Primary Treatment: Clinical Implications for Salvage Radiation Therapy. Eur Urol Oncol. 2020. PMID: 32451312. doi:10.1016/j.euo.2020.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。